Article Text

PDF

Clinical and research medicine: Cardiovascular clinical pharmaceutical research
e0350 Effects of Probucol on anti-oxidising and anti-inflammation in patients with acute coronary syndrome
  1. Yan Kaili,
  2. Liu Hanhua,
  3. Sun Yueling,
  4. Chen Su,
  5. Tu Yuanchao
  1. Xinhua Hospital of Hubei Province

Abstract

Objective To observe the effects of probucol on blood levels of oxidative low density lipoprotein antibody (oxLDL-Ab), high-sensitive C-reactive protein (hs-CRP) and interleukin-18 (IL-18) in patients with acute coronary syndrome (ACS).

Methods 81 patients with ACS were divided randomly into a Probucol treatment group (p group, n=41) and a routine treatment group (R group, n=40). OxLDL-Ab, hs-CRP and IL-18 were respectively measured in peripheral blood before therapy. The level of OxLDL-Ab was measured again after a 4-week treatment. The levels of hs-CRP and IL-18 were measured again after 1-week treatment. The frequency of typical angina of p group and R group in the last week of treatment was analysed.

Results The levels of oxLDL-Ab, hs-CRP and IL-18 were obviously lower in p group compared with R group after treatment (p<0.05). The frequency of typical angina of p group in the last week of treatment was obviously lower than that of R group, and this was closely correlated with the decreased oxLDL-Ab values (p<0.05).

Conclusion Probucol had anti-oxidant and anti-inflammatory action in patients with ACS.

  • Probucol
  • acute coronary syndrome
  • oxidative low density lipoprotein antibody
  • high-sensitive C-reactive protein
  • interleukin-18

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.